Clinical Trial

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-23; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2022-04-18
Trial Details
NCT Number NCT05018520
Lead Sponsor Ruijin Hospital
Conditions Diffuse Large B Cell Lymphoma
Enrollment 640 participants
Start Date 2021-09-17
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11